

Review of the Patient Burden and Therapeutic Landscape of Irritable Bowel Syndrome with Constipation in the United States [Corrigendum]

Sendzischew Shane MA, Ruddy J, Cline M, Rosenbaum DP, Edelstein S, Moshiree B. *Clin Exp Gastroenterol*. 2024;17:227–253.

The authors have advised of errors in Figure 2 on page 234. Under the US FDA-approved prescription medications, Chloride channel agonists subsection is incorrect. A new subsection “Guanylate cyclase agonists” should be included and “Lifestyle interventions” should read “Linaclotide”. The correct Figure 2 is presented as follows.

Nonpharmacologic interventions	US FDA-approved prescription medications	AGA clinical practice guidelines
1 Lifestyle interventions ^a ---	Chloride channel agonists	1 AGA-suggested initial/first-line (mild) treatment for IBS-C
1 Dietary modifications (eg, low-FODMAP diet) IBS	2 Lubiprostone IBS-C	2 AGA-suggested second-line (moderate) treatment for IBS-C; selection should be based on clinical features and patient needs
	Guanylate cyclase agonists	✓2 AGA-recommended second-line (moderate) treatment for IBS-C; selection should be based on clinical features and patient needs
	✓2 Linaclotide IBS-C	AG-suggested treatment for IBS-C if abdominal pain and/or psychological symptoms persist; selection should be based on clinical features and patient needs
OTC therapies	2 Plecanatide IBS-C	ⓘ AGA suggest against use for the treatment of IBS
1 Osmotic laxatives (eg, PEG) X	Sodium channel antagonists	--- No AGA guidance provided
1 Antispasmodics X	2 Tenapanor ^b ---	
1 Peppermint oil IBS	Brain-gut behavioral and neuromodulator therapies	
1 Soluble fiber IBS	Tricyclic antidepressants IBS	IBS ACG-recommended treatment for global IBS symptoms
	SNRIs ---	IBS-C ACG-recommended treatment for global symptoms in patients with IBS-C
Other therapies	Brain-gut behavioral therapies (eg, CBT, hypnosis) IBS	IBS ACG-suggested treatment for global IBS symptoms
--- Probiotics X	X SSRIs ---	X ACG suggest/recommend against use for the treatment of IBS/IBS-C symptoms
		--- No ACG guidance provided

Figure 2 Treatment recommendations for IBS-C according to current US guidelines.^{1,62,63} Note that although tegaserod is included in the guidelines, it has been omitted from this figure as it has been withdrawn from the market and is unavailable for prescription. ^aLifestyle modification suggested by the AGA: exercise, sleep, stress reduction. ^bAt the time of preparation of the most recent ACG guidelines, the amount of real-world clinical practice experience with tenapanor available for consideration by the ACG would have been limited (tenapanor received FDA approval for use in 2019).

Abbreviations: ACG, indicates American College of Gastroenterology; AGA, American Gastroenterological Association; CBT, cognitive behavioral therapy; FDA, Food and Drug Administration; FODMAP, fermentable oligosaccharides, disaccharides, monosaccharides, and polyols; IBS, irritable bowel syndrome; OTC, over-the-counter; PEG, polyethylene glycol; SNRI, serotonin-norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; US, United States.

The authors apologize for this error.

Clinical and Experimental Gastroenterology

Dovepress

Publish your work in this journal

Clinical and Experimental Gastroenterology is an international, peer-reviewed, open access, online journal publishing original research, reports, editorials, reviews and commentaries on all aspects of gastroenterology in the clinic and laboratory. This journal is indexed on American Chemical Society's Chemical Abstracts Service (CAS). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/clinical-and-experimental-gastroenterology-journal>

<https://doi.org/10.2147/CEG.S506887>